Find out more about the evidence that supports the use of TAVI to treat patients with severe aortic stenosis (sAS).1-8 TAVI has been shown to benefit a wide range of sAS patients, including those with differing levels of surgical risk, patients with the typical comorbidities and risk factors associated with sAS.6-11

TAVI trials

Discover more about the trials that have demonstrated comparable or better outcomes with TAVI compared with surgery (sAVR) in sAS patients with low, intermediate or high surgical risk. In addition, see the trial of TAVI versus standard treatment in patients with inoperable aortic stenosis.1-8

Low risk


Intermediate risk


High risk




Quality of life

At 1 month post-intervention, health status was significantly better in patients who underwent TAVI compared to those who underwent sAVR. TAVI was also associated with health status benefits at 12 months compared with sAVR in low surgical risk patients.12-14

Read more

Healthcare system impact

Examine the data that show TAVI has a number of benefits for healthcare systems. This includes low complication rates9, shorter procedure time10, faster recovery12 and reduced length of hospital stays.3,5

Read more

TAVI valve durability

Valve durability is a key consideration for intervention choice. Assess the follow-up data from the PARTNER 3 studies, which establish the durability of the SAPIEN valves used in TAVI5,6

Read more

Stay informed with our newsletter

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.Read more


1 Leon MB, Smith CR, Mack M, et al. N Engl J Med 2010; 363:1597-1607.
2 Smith CR, Leon MB, Mack MJ, et al. N Engl J Med 2011;364:2187-2198.
3 Leon MB, Smith CR, Mack MJ, et al. N Engl J Med 2016;374:1609-1620.
4 Kapadia SR, Leon MB, Makkar RR, et al. Lancet 2015;385:2485-2491.
5 Thourani VH, Kodali S, Makkar RR, et al. Lancet 2016;387:2218-2225.
6 Mack MJ, Leon MB, Smith CR, et al. Lancet 2015;385:2477-2484.
7 Webb JG, Doshi D, Mack MJ, et al. JACC Cardiovasc Interv 2015;8:1797-1806.
8 Mack MJ et al. N Engl J Med. 2019;380(18):1695-1705.
9 Tamburino C, Barbanti M, Capodanno D et al. Am J Cardiol 2012;109:1487–1493.
10 Hamm CW, Möllmann H, Holzhey D et al. Eur Heart J 2014;35:1588–1598.
11 Kleczyński, P, Bagieński M, Sorysz D, et al. Kardiol Pol 2014;72:612–616.
12 Baron SJ, Magnuson EA, Lu M, et al. J Am Coll Cardiol 2019;74(23):2833-2842.
13 Baron SJ, Arnold SV, Wang K, et al. JAMA Cardiol 2017;2:837-845.
14 Reynolds MR, Magnuson EA, Wang K, et al. J Am Coll Cardiol 2012;60:548-558.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult where applicable).

PP--EU-0768 v2.0